Bruker, Primer Design ink European distribution deal for coronavirus test

By staff writers

March 25, 2020 -- Bruker has signed an agreement with U.K.-based Primer Design for Bruker-Hain Diagnostics to distribute the genesig real-time polymerase chain reaction (PCR) assay for the novel coronavirus.

The CE-IVD assay is designed for use on Bruker-Hain Diagnostics' GenoXtract (GXT) automated nucleic acid extraction devices with associated extraction kits, and it targets very high specificity for SARS-CoV-2, the virus implicated in the respiratory disease COVID-19. It is validated for respiratory samples (nasopharyngeal swabs, oropharyngeal swabs, and sputum) on commonly available laboratory thermocyclers. The kit includes all necessary reagents to produce up to 96 results in under two hours, according to the companies.

Primer Design, which is a subsidiary of Novacyt, has already begun shipments to Spain, France, Germany, and the U.K.

HHS awards $100M to deal with coronavirus, including testing
The U.S. Department of Health and Human Services (HHS) has awarded $100 million in grants to certain health centers to cover screening and testing...
CDC accelerates effective date of COVID-19 code
The novel coronavirus pandemic has prompted the U.S. Centers for Disease Control and Prevention (CDC) to move up to April 1 the adoption date for a diagnosis...
FDA sounds alarm on fake home test kits for coronavirus
The U.S. Food and Drug Administration (FDA) has alerted consumers to the sale of fake and unauthorized home test kits for the novel coronavirus and COVID-19...
AACC preview: A rough guide to diagnostics on show
Bruce Carlson, longtime diagnostic market analyst and publisher of Kalorama Information, takes you on a trip through this year's product offerings at...

Copyright © 2020

Last Updated np 3/25/2020 4:16:45 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current